Who We Are
At our core is perseverance, a fierce determination to overcome any obstacle regardless of setbacks, on behalf of patients and their loved ones. We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.
We are doing everything in our power to live up to our mission in three important categories.
Our driving philosophy at Otsuka is to serve those with unmet medical needs, and that couldn’t be more true than in our dedication to the central nervous system (CNS) space. In our 30 years of experience working in this therapeutic area, we continue to innovate and defy limitation by taking risks to overcome the complexities of treating mental health. We respect the value within every mind and are committed to making a difference in the lives of patients living with schizophrenia, major depressive disorder, bipolar disorder, and other CNS conditions.
When Otsuka saw a need for clinical expertise and research in the nephrology space, we decided to lead the way. For more than 20 years, we have been bringing our research and expertise to this therapeutic area. We have focused on developing novel drugs in areas of unmet need, such as autosomal dominant polycystic kidney disease and hyponatremia, that have changed the treatment landscape. Our long-term perseverance has led to major breakthroughs, giving patients renewed hope and clinicians more options than ever before.
Digital technology has not only changed the world we live in, but it is also changing the face of healthcare. Otsuka is at the forefront of this transformative juncture in medicine, creating novel solutions that help address the challenges of those living with serious mental illness. We believe our investment and leadership in this therapeutic area will revolutionize patient care as we know it. Patients will be able to engage and communicate with their care teams in new ways, and clinicians will have data-driven insights that may help inform treatment decisions.
Busaburo Otsuka founded Otsuka in Tokushima Prefecture, Japan, with an unconventional idea and the belief that anything is possible. Otsuka has been on a journey of creativity and innovation ever since.
The first Otsuka US research and development base was established in Rockville, Maryland. Just a few years later, in 1989, Otsuka’s first US commercial organization was created, Otsuka America Pharmaceutical, Inc (OAPI).
Otsuka’s second US location, in Princeton, New Jersey, was opened. We continued our evolution, and in 2007 Otsuka Pharmaceutical Development & Commercialization, Inc (OPDC), was created to oversee all commercial pharmaceutical and medical device activities in the United States.
Today the two companies, OAPI and OPDC, are part of one family—the Otsuka Holdings Co, Ltd, that has over 180 companies, with more than 45,000 employees in 28 countries around the world.
Our Family of Companies
Our parent, Otsuka America, Inc (OAI), consists of multiple companies committed to offering innovative products that go beyond healthcare to improve the health and well-being of patients. Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development, Inc. (OPDC) belong to a distinguished family of US affiliates.